Hints and tips:
...The Development Bank of Japan is investing in 4Bio, which funds companies in the UK and Europe, alongside the Japanese pharma group Kyowa Kirin, and US healthcare provider, Children’s Minnesota. 4Bio aims...
...Astellas Pharma has agreed to buy US biotech group Iveric Bio for roughly $5.9bn, marking the Japanese drugmaker’s largest-ever acquisition and giving it access to the rapidly expanding market for age-related...
...In February, Kirin spent $1.2bn to buy a 95 stake in biochemicals company Kyowa Hakko Bio, and then in September spent the same amount to acquire a 33 per cent stake in cosmetics and health supplement company...
...Sure there is a brief high — see the growing profit at pharmaceutical subsidiary Kyowa Hakko Kirin. But medicines require hefty R&D spend with an uncertain outcome....
...Fujifilm has teamed up with a Japanese pharma company, Kyowa Hakko Kirin Biologics, and said that, by merging technologies developed through its photographic film business with Kyowa’s expertise in biopharma...
...Among big name companies poised to enter the market with their versions of the drug are Japan’s Fujifilm Kyowa Kirin Biologics, which has granted Mylan an exclusive licence to commercialise Hulio in Europe...
...Pharmaceutical stocks have been among the biggest movers, with Eisai up 81 per cent and Kyowa Hakko Kirin rising 54 per cent....
...Smaller Japanese rival Kyowa Hakko Kirin already owns the rights for Tivozanib’s sales in Asia....
...Prostrakan , the maker of testosterone gel, tranquillisers and rectal ointment, rose 20.8 per cent to 131½p after it agreed to a 130p-per-share bid from Japanese pharmaceuticals group Kyowa Hakko Kirin....
...The board of ProStrakan, a speciality pharmaceutical company based in the Scottish borders, is recommending a £292m ($474m) cash offer from Tokyo-based Kyowa Hakko Kirin (KHK)....
...Schincariol is not Japan Inc’s first brush with tough acquisitions....
...Under his leadership, Kirin aggressively pursued acquisitions, buying Australia’s National Foods, San Miguel Brewery in the Philippines and Kyowa Hakko, a Japanese pharmaceuticals group....
...Kyowa Hakko Kirin fell 4.3 per cent to Y921 after the drugmaker said it was likely to have missed its nine-month profit estimate....
...Kirin has spent Y440bn ($4.9bn) on acquisitions in the past year, paying Y170bn for a 50.1 per cent stake in Kyowa Hakko, a Japanese food and chemicals company, and Y220bn for National Foods in 2007, and...
...Japan Inc has relatively modest gearing of 0.5 times; about half of companies have net cash....
...This year, Kirin, the beverage group, acquired Kyowa Hakko, a midsize drugmaker....
...The beer maker plans to merge Kyowa Hakko with its pharmaceuticals arm, Kirin Pharma....
...The purchase is Kirin’s second outside the beer industry in less than a month, following a similar-sized offer in October for control of Kyowa Hakko, a Japanese drugs maker....
...Shares in Kyowa Hakko Kogyo, a drug maker, soared 16.7 per cent to Y1,402 after the Nikkei reported that Kirin, the beer maker, would take a majority stake in the company....
...The purchase is Kirin’s second outside the beer industry in less than a month, following an offer in October for control of Kyowa Hakko, a Japanese drugs maker....
...Analysts say Kirin’s relationship with its bankers is solid enough to fund a San Miguel deal even after the Kyowa Hakko and National Foods purchases....
International Edition